The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC.
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Seagen; Takeda; Turning Point Therapeutics; Xcovery
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Roche; Seagen; Takeda; Turning Point Therapeutics; Xcovery
Research Funding - ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics; MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell; Turning Point Therapeutics (Inst)
Expert Testimony - Merck KGaA; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Peptomyc; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; PeerVoice; Pfizer; Roche; Takeda
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRÍFOLS
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Research Funding - Boehringer Ingelheim; Genentech/Roche; Ignyta; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Merck; Pfizer; Takeda
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus therapeutics; Guardant Health; J INTS BIO; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Martin Wermke
Honoraria - Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cellex GmbH; GEMoaB; immatics; ISA Pharmaceuticals; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; GEMoaB; Pfizer; Roche
 
Adrianus De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merus (Inst); MSD Oncology (Inst); Roche (Inst)
 
Roberto Ferrara
Consulting or Advisory Role - BeiGene; Merck Sharp & Dohme
 
Stephan Kanzler
No Relationships to Disclose
 
Fabiana Letizia Cecere
No Relationships to Disclose
 
Domenico Galetta
Speakers' Bureau - Astra Zeneca Italia; BMS Italy; Lilly; MSD Oncology; Roche
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GC Pharma; Lilly; Menarini; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda
Consulting or Advisory Role - ST Cube
 
Vanesa Gregorc
No Relationships to Disclose
 
Ana Rodrigues
No Relationships to Disclose
 
Christian Britschgi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Janssen-Cilag; Pfizer; Roche; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Takeda
 
Ahmadur Rahman
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Diana Ndunda
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Johannes Noe
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Danny Lu
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); cergentis (Inst); Chugai Pharma (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)